{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:21:04Z","timestamp":1790673664764,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/ftd.0b013e3181b2c8cf","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T03:18:02Z","timestamp":1253589482000},"page":"579-584","source":"Crossref","is-referenced-by-count":81,"title":["A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times"],"prefix":"10.1097","volume":"31","author":[{"given":"Yanfeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Lin","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Nedelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Schran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.healun.2005.11.460","article-title":"Therapeutic drug monitoring of prednisolone after lung transplantation.","volume":"25","author":"Morton","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"R2-8-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/clpt.1988.42","article-title":"Therapeutic drug monitoring.","volume":"43","author":"Spector","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"R3-8-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1078155207081133","article-title":"Therapeutic drug monitoring of cancer chemotherapy.","volume":"13","author":"Alnaim","year":"2007","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl 1","key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"75S","DOI":"10.1111\/j.1365-2125.2001.00366.x","article-title":"Therapeutic drug monitoring of cytotoxic drugs.","volume":"52","author":"Lennard","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R5-8-20210129","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"R6-8-20210129","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate-A new oral targeted therapy.","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"R8-8-20210129","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"R9-8-20210129","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","article-title":"Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis.","volume":"130","author":"Miettinen","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"R10-8-20210129","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: A subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R12-8-20210129","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels correlate with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors.","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity.","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.hoc.2004.03.014","article-title":"Imatinib therapy in chronic myeloid leukemia.","volume":"18","author":"Crossman","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","article-title":"Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: Results of a phase III study.","volume":"60","author":"Schmidli","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R19-8-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","article-title":"Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.","volume":"55","author":"Judson","year":"2005","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181b2c8cf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T03:42:13Z","timestamp":1739331733000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200910000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181b2c8cf","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}